Amenorrhea pathophysiology
Jump to navigation
Jump to search
|
Amenorrhea Microchapters |
|
Patient Information |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Amenorrhea pathophysiology On the Web |
|
American Roentgen Ray Society Images of Amenorrhea pathophysiology |
|
Risk calculators and risk factors for Amenorrhea pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Amenorrhea is defined as absence of menstrual cycle. The causes of amenorrhea include hypothalamic, pituitary, thyroid, adrenal, ovarian, uterine, and vaginal. About 25 different genes are involved in the pathogenesis of amenorrhea including 3 different groups of Kallmann syndrome related genes, hypothalamus-pituitary-gonadal (HPG) axis related genes, and obesity related genes. On gross pathology, normal endometrium is the characteristic findings of amenorrhea. Patients of amenorrhea from Craniopharyngioma as have cystic mass filled with motor oil-like fluid on gross pathology. On microscopic histopathological analysis, craniopharyngioma presents as trabecular squamous epithelium surrounded by palisaded columnar epithelium, small-to-medium sized cells with moderate amount of basophilic cytoplasm, bland nuclei, and calcifications. On microscopic histopathological analysis, pituitary adenoma as a cause of amenorrhea presents as loss of fibrous stroma and nested cells of normal anterior pituitary (based on the type of adenoma).
Pathophysiology
Physiology of normal puberty
Menarche and Menstruation
- The mean age for onset of menstruation is 12.43 years in US. About 80% of females experience menarche between 11 and 13.75 years of age.[1]
- Almost all (98%) of females experience menarche by the age of 15.[2]
- Gonadotropin releasing hormone (GnRH) is the main factor in puberty onset.
- GnRH is secreted by the neurosecretory neurons of hypothalamus into the hypophysial portal system, from where it is transferred to anterior pituitary gland.
- GnRH stimulates production and secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH).
- During puberty the amplitude and frequency of GnRH pulses is significantly increased.
- GnRH secretion is regulated by certain neurotransmitters in brain, such as dopamine, endogenous opioids, norepinephrine, gamma amino butyric acid (GABA), and corticotropin releasing hormone (CRH). Alteration in level and function of these neurotransmitters may lead to specific types of amenorrhea. For example stress, exercise, and malnutrition affects CRH, β-endorphin, and dopamine, respectively.[3]
- After the onset of puberty, the negative feedback on GnRH is removed.
- Pulsatile secretion of GnRH induce LH and FSH production which finally lead to ovulation.
- In the absence of fertilisation, the ovarian follicle is turned into corpus luteum. Endometrium proliferates through estrogen release from corpus luteum. Withdrawal of progesterone from estrogen-mediated proliferated endometrium results in menstrual bleeding.
Hypothalamic-pituitary-ovarian (HPO) axis maturation
- After activation of the HPO axis during second trimester of pregnancy, the level of gonadotropins rises from mid to term pregnancy. After cessation of placental hormone feedback, FSH and LH increases again slightly to mild secondary peak.
- Before puberty, negative feedback from adrenal androgens keep the gonadotropins in low plasma level.[4]
- Right before puberty, the sensitivity of hypothalamus to negative feedback from adrenal androgens is decreased. This leads to increased production of GnRH from hypothalamus and make it possible for GnRH to be raised in magnitude and frequency to induce an increase in LH and FSH.[5]
- The complete maturation of HPO axis takes around 5-7 years from the onset of menstruation. Generally, during the first two years of menstruation, the cycles are mostly anovulatory due to immature HPO axis.
Pathogenesis
- Amenorrhea is defined as the absence of menstrual cycle.[3]
- Primary amenorrhea is the absence of menstrual cycle by 16 years of age, in the presence of normal growth and secondary sexual characteristics.
- Secondary amenorrhea reflects absence of menstrual cycle for at least 3 months in a woman with normal menstruation cycles in the past.
- The pathophysiology of amenorrhea is multifactorial and include hypothalamic, pituitary, thyroid, adrenal, ovarian, uterine, and vaginal causes.
Hypothalamic pathogenesis
- The most common cause of amenorrhea in adolescents are hypothalamic disorders and is known as hypothalamic amenorrhea.
- During the initial 2-3 years after the onset of menarche, the HPO axis is still under development. Immature HPO axis may lead to anovulatory cycles which can cause abnormalities in menstrual cycles.
- The most common cause of amenorrhea after 2-3 years of onset of puberty include eating disorders, excessive exercise, medications, and psychosocial stress.[6][7]
- Leptin plays an important role in energy consumption, body composition, food intake along with sexual maturation and reproductive improvement.
- It is assumed that leptin plays a role in the development of hypothalamic amenorrhea.
- Leptin receptors are in close relationship with hypothalamus and it is postulated that leptin regulates GnRH production and secretion.
- Patients with anorexia nervosa or excessive exercise have amenorrhea from down-regulation of leptin receptors, which can be elevated by refeeding.[8][9][10]
- Leptin level in cachexic patients will increase after gaining appropriate weight in patients without amenorrhea, but will remain low in patients with amenorrhea.[11][12]
- It has been observed that leptin levels in amenorrheic athletes are low as compared to non-athletes women or athletes with regular menses.[13][14]
- Administration of recombinant leptin for 3 months in women with conditions such as hypothalamic amenorrhea, excessive exercises or weight loss has been associated with an increased level of LH, FSH, and estradiol leading to ovulatory cycles.[15]
- Antipsychotic drugs and other medications that have an inhibitory effect on dopamine D2 receptor lead to an increased level of prolactin. Higher levels of prolactin suppress pulsatile GnRH secretion and block positive feedback of estradiol on hypothalamus, leading to disruption of HPO axis.[16]
- Stress and strenuous activities like other metabolic or cardiovascular responses are regulated through corticotropin releasing hormone (CRH), secreted by paraventricular nuclei of hypothalamus. CRH induce the release of β-endorphin, an endogenous opioid. Both CRH and β-endorphin suppress GnRH release. On the other hand, glucocorticoids suppress LH production from pituitary and also estrogen/progesterone from ovaries.[17]
- Kallmann syndrome, a genetic disorder caused by KAL gene mutation, has disturbance in migration of olfactory nerves along with GnRH neurons. Lack of GnRH leads to absence of secondary sexual characteristics and amenorrhea.[18]
Pituitary pathogenesis
- Prolactinoma is one of the most common anterior pituitary tumors. Prolactinoma leads to increased prolactin secretion and along with the tumor's mass effect may cause suppression of GnRH.
- The second most common tumor in the suprasellar region is craniopharyngioma. The tumor leads to LH and FSH disturbances, which may cause amenorrhea.[19]
Thyroid pathogenesis
- In hypothyroidism, the main mechanism that can lead to amenorrhea is the influence of thyrotropin releasing hormone (TRH) on lactotroph cells, increasing prolactin levels. Since the TRH is increased in hypothyroidism, it leads to functional hyperprolactinemia. The increase in prolactin may suppress the GnRH pulsatility and lead to amenorrhea.[20]
- In hyperthyroidism, the mechanism of amenorrhea is not clear. It is assumed that increased level of sex hormone binding globulins (SHBGs) in hyperthyroidism may lead to increased levels of androgens and estrogen. Conclusively, the LH surge become absent and amenorrhea happens.[21]
Adrenal pathogenesis
- Congenital adrenal hyperplasia (CAH) is a group of genetic enzyme deficiencies in adrenal gland. Most common is the defect in 21-hydroxylase enzyme, which leads to decrease in the level of aldosterone and cortisol. To overcome the hormone deficiencies, CRH production is increased by the hypothalamus. As described earlier, increased level of CRH may suppress GnRH and lead to amenorrhea.[22]
- Cushing syndrome has an increased level of cortisol, that can directly inhibit HPO axis and lead to amenorrhea.
Ovarian pathogenesis
- In polycystic ovary syndrome (PCOS) insulin resistance leads to increased androgen production (insulin reduces the SHBG circulating in plasma, causing increased testosterone). In ovaries, increased stimulation from GnRH leads to increased production of 17-hydroxy progesterone and cytochrome P450c17 which promotes androgens biosynthesis.[23][24] Finally, the pulsatility of GnRH will be disrupted leading to amenorrhea .[25]
- Primary ovarian insufficiency is multifactorial and leads to ovarian failure and decrease in estrogen which leads to amenorrhea. (In galactosemia, it is assumed that galactose and its metabolites are toxic to ovarian tissue.)[26]
Uterine pathogenesis
- The main pathogenesis of amenorrhea in androgen insensitivity syndrome is the absence of uterus. The patient is genotypically male, 46 XY; but with absent sexual characteristics due to lack of functional effect of androgen hormones on their receptors.
- One of the acquired conditions that can lead to amenorrhea is Asherman syndrome. The basis of Asherman syndrome is any condition that can alter the normal histology of endometrium, such as scarring from surgical procedure or adhesion from severe infection.
- Mayer-Rokitansky-Kuster-Hauser syndrome is complete agenesis of uterine, blind ended vagina. The lack of uterine and endometrium is the main pathogenesis of amenorrhea. The main reason of uterine agenesis is overactivation of anti-mullerian hormone in embryogenesis period.[27] Cervical agenesis also follow the similar process.
- Imperforated hymen, transverse vaginal septum, and vaginal agenesis are other anatomical disorders of female reproductive system that can lead to amenorrhea.[28]
Genetics
The major genes in amenorrhea
| Groups | Gene | Other name(s) | OMIM number | Chromosome | Function | Other related disorders |
|---|---|---|---|---|---|---|
| Kallmann syndrome
and Isolated hypogonadotropic hypogonadism[29] |
KAL1 | KAL1, anosmin-1 | 308700 | Xp22.3 |
|
|
| FGFR1 | KAL2 | 136350 | 8q12 |
|
| |
| PROKR2 | KAL3 | 607123 | 20p13 |
|
||
| PROK2 | KAL4 | 607002 | 3p21.1 | |||
| CHD7 | KAL5 | 608892 | 8q12.1 |
|
| |
| FGF8 | KAL6 | 600483 | 10q24 |
|
| |
| GPR54 | KISS1R | 604161 | 19p13.3 |
|
- | |
| KISS1 | KISS1, kisspeptin1 | 603286 | 1q32 |
|
- | |
| HS6ST1 | - | 604846 | 2q21 |
|
- | |
| TAC3 | NKB | 162330 | 12q13–q21 |
|
||
| TACR3 | NK3R | 152332 | 4q25 | |||
| GnRH1 | - | 152760 | 8p21–8p11.2 |
|
| |
| GnRHR | - | 138850 | 4q21.2 |
|
||
| NELF | - | 608137 | 9q34.3 | - | ||
| EBF2 | - | 609934 | 8p21.2 |
|
- | |
| HPG axis development | DAX1 | NR0B | 300473 | Xp21.2 |
|
|
| SF-1 | NR5A1 | 184757 | 9q33.3 |
|
||
| HESX-1 | RPX | 601802 | 3p14.3 |
|
| |
| LHX3 | LIM3 | 600577 | 9q34.3 |
|
| |
| PROP-1 | - | 601538 | 5q35.3 |
|
| |
| Obesity related
hypogonadotropic hypogonadism |
LEP | OB | 164160 | 7q32.1 |
|
|
| LEPR | OBR | 601007 | 1p31.3 | |||
| PC1 | NEC1 | 162150 | 5q15 |
|
| |
|
Abbreviations (alphabetic): | ||||||
Kisspeptin system (KISS1R and KISS1)
- The GPR54 gene, also called KISS1R, with Online Mendelian Inheritance in Man (OMIM) number of 604161 is on chromosome 19p13.3. The KISS1 gene, also known as kisspeptin1, with OMIM number of 603286 is on chromosome 1q32.
- Kisspeptin and related G-protein coupled receptor (KISS1R or GPR54) have key roles in the regulation of GnRH secretion. The GnRH secretion has to be pulsatile to stimulate gonadotropins. Kisspeptins are encoded by KISS1 gene, neuropeptides secreted from hypothalamus nuclei. It has been observed that patients with idiopathic hypogonadotropic hypogonadism have KISS1 receptor (GPR54) inactivating gene mutations.[30][31]
- By the time of onset of puberty, the KISS1 genes become activated through neuroanatomical and functional changes from environmental triggers, critical for brain sexual maturation and hypothalamic–pituitary–gonadal axis (HPG axis) activation with pulsatile GnRH.[32]
- Along HPG axis neurons, gamma-aminobutyric acid is inhibitory and glutamate is excitatory neurotransmitters. In related KNDy neurons in arcuate nucleus, the materials secreted are included kisspeptin, neurokinin B, and dynorphin A. Before puberty begins, inhibitory dynorphin A is the dominant element; decreased by stimulatory effect of neurokinin B, when puberty started. Conclusively, kisspeptin and GnRH/LH are increased.[33]
Kallmann syndrome 1 (KAL1)
- The KAL1 gene, also called anosmin-1, with OMIM number of 308700 is on chromosome Xp22.3, and encodes an extracellular matrix glycoprotein.
- Anosmin-1 is expressed at five weeks of gestation in forebrain near olfactory bulbs and stimulate the afferent fibers projections around it.[34]
- X-linked Kallmann syndrome is directly associated with KAL1 deletion. It is assumed to result in an absence of olfactory fibers along with disrupted migration of GnRH neurons, that are supposed to from migrated olfactory placode.[35]
- Male patient with KAL1 mutation would have central hypogonadism and anosmia/hyposmia. Additionally, the more diseases are assumed to relate with KAL1 gene, such as midline facial defects (cleft lip and/or cleft palate), short metacarpals, renal agenesis, sensorineural hearing loss, bimanual synkinesis, oculomotor abnormalities, and cerebellar ataxia.[36]
Fibroblast growth factor receptor 1 and fibroblast growth factor 8 (FGFR1 and FGF8)
- The FGFR1 gene, also called KAL2, with OMIM number of 136350 is on chromosome 8q12, encode a receptor tyrosine kinase protein. The FGF8 gene, also called KAL6, is on chromosome 10q24.
- FGFR1 pathway is assumed to be the main role in embryogenesis, homeostasis, and wound healing. FGF8 plays a critical role in the primary generation of neural tissue.[37]
- On the other hand, interaction between FGFR1, FGF8, and heparan sulfate helps the olfactory bulb to become differentiated and developed and also facilitates GnRH neurons in migration and function.[38]
- Dominant deletion mutation of FGFR1 gene is associated with a 30% decrease in hypothalamic GnRH neurons.[39] Other defects related to FGFR1 includes cleft palate or lip, dental agenesis and bimanual synkinesis.[36]
Heparan sulfate 6-O-sulphotransferase 1 (HS6ST1)
- The HS6ST1 gene with OMIM number of 604846 is on chromosome 2q21 has been found to be mutated in hypogonadism.[40]
- The modifications of heparan sulfate polysaccharides in extracellular matrix have some role in FGFR-FGF and also anosmin1-cell membrane interactions.[41][42]
- This gene may be mutated in both Kallmann syndrome and idiopathic hypogonadism resulting in various courses, disruption pf frequency of GnRH secretion, and/or GnRH deficiencies.[40]
Prokineticin 2 and prokineticin 2 receptor (PROK2 and PROKR2)
- The PROK2 and PROKR2 genes, also called KAL4 and KAL3, with OMIM numbers of 607002 and 607123 are on chromosomes 3p21.1 and 20p13, respectively. They are believed to be a cause of Kallmann syndrome.
- PROKR2 is a G protein coupled receptor (GPCR), has a major role in olfactory bulb development; and its mutation may lead to severe gonadal atrophy.[43]
- In prokineticin system, there are two receptors (PROKR1 and PROKR2) and two ligands (PROK1 and PROK2). PROK1 and its receptor (PROKR1) have some role in gastrointestinal system motility. PROK2 and PROKR2 are parts of neuroendocrine system, located in arcuate nucleus, olfactory tract, and suprachiasmatic nucleus.[44]
- The mutated versions of PROK2 and PROKR2 could lead to decrease GnRH production and hypogonadism. Other disorders caused by PROK2 and PROKR2 mutations include fibrous dysplasia, sleep disorder, severe obesity, synkinesis, and epilepsy.[45]
Tachykinin 3 and tachykinin 3 receptor (TAC3 and TACR3)
- The TAC3 and TACR3 genes, also called neurokinin B (NKB) and neurokinin 3 receptor (NK3R), with OMIM numbers of 162330 and 152332, are on chromosomes 12q13–q21 and 4q25, respectively.[46]
- It is postulated that the normal function of TAC3/TACR3 system is necessary for an intact HPG axis and its development during puberty. On the other hand, TAC3/TACR3 system disturbance may cause micropenis and cryptorchidism in males, showing the major role of TAC3/TACR3 in fetal gonadotropins secretion.[47]
- TACR3 encoded protein (NK3R) is GPCR, initially produced in central nervous system. The major mechanism, through which the mutated gene may lead to neuroendocrine disturbance and delayed puberty, is not yet discovered completely.[48]
- TAC3 encoded protein (NKB) is produced in arcuate nucleus of hypothalamus and play an important role in GnRH secretion. Kisspeptin is also produced and secreted in arcuate nucleus, whereas, both of them are inhibited by estrogen. It may be considered that kisspeptin and NKB have identical roles in diverting negative feedback from sex hormones to GnRH. Their mutation has been shown to be related with hypogonadism.
Gonadotropin releasing hormone and its receptor (GnRH1 and GnRHR)
- The GnRH1 and GnRHR genes with OMIM numbers of 152760 and 138850 are on chromosomes 8p21–8p11.2 and 4q21.2, respectively.[49]
- In HPG axis, GnRH is one of the most effective elements; therefore, a defect could directly influence the axis and slow down the progress.
- The GnRHR gene is also responsible for gonadal normal functions and its mutation could lead to hypogonadism and delayed puberty. The mutation in GnRHR has also been associated with conditions such as atrophic gonads along with low LH/FSH and sex hormones, sexual puberty disturbance, inability to conceive, and failure to impact from exogenous GnRH.[50]
- GnRH1 and GnRHR genes have variable expression and cause a spectrum of symptoms, from fertile eunuch syndrome and partial idiopathic hypogonadotropic hypogonadism to complete GnRH resistance (i.e., characterized by cryptorchidism), microphallus, very low LH/FSH, and delayed puberty.[51]
- The other disorders that have been found to be related to GnRH mutation are tooth maturation and biomineralization.[52]
Chromodomain helicase DNA-binding protein 7 (CHD7)
- The CHD7 gene, also called as KAL5, with OMIM number of 608892 is on chromosome 8q12.1.
- CHD7 gene mutation results in autosomal dominant CHARGE syndrome, which is a combination of hypogonadism and Kallmann syndrome, and includes:[53]
- Coloboma
- Heart anomalies
- Choanal Atresia
- Retardation
- Genital anomalies
- Ear anomalies
- Screening for CHD7 gene mutation may be done in patients with hypogonadism or Kallmann syndrome with specific features such as semicircular canal hypoplasia or aplasia, dysmorphic ears, and deafness.
Nasal embryonic LH-releasing hormone factor (NELF)
- The NELF gene with OMIM number of 608137 is on chromosome 9q34.3; present mostly in nervous tissues specifically during fetal development and may be found in olfactory bulb and pituitary LH releasing cells.
- The most common function is in olfactory axons and GnRH neurons, before and during neuron migration in the developmental process.[54]
Early B-cell factor 2 (EBF2)
- The EBF2 gene with OMIM number of 609934 is on chromosome 8p21.2; mostly expressed in mice osteoblasts and osteoclast cells.[55]
- EBF2 gene plays an effective role in HPG axis. Mutation in EBF2 gene can result in disruption of HPG axis, leading to secondary hypogonadism.[56]
DSS-AHC on the X-chromosome 1 (DAX1)
- The DAX1 gene, also called nuclear receptor 0B (NR0B), with OMIM number of 300473 is on chromosome Xp21.2, and expressed in all members of HPG axis (hypothalamus, pituitary, and gonads).[57]
- During the spermatogenesis and steroidogenesis, both sertoli and leydig cells have increased expression of DAX1 gene. It is assumed that during puberty, the peak expression of DAX1 is observed.[58]
- Other disease that can be caused by DAX1 mutation is congenital adrenal cortex hypoplasia.[59]
Steroidogenic factor 1 (SF1)
- The SF1 gene, also called nuclear receptor 5A1 (NR5A1), with OMIM number of 184757 is on chromosome 9q33.3, has some role in reproduction, steroidogenesis, and sexual differentiation.
- It is mainly expressed in sertoli and leydig cells, and plays an important role in steroidogenesis and spermatogenesis. The SF1 is believed to have an increase in expression from childhood until adolescence, and is dominantly expressed by leydig cells in puberty.[58]
- Other diseases that may be caused by SF1 mutation include male pseudohermaphroditism, Denys-Drash syndrome, and also hypospadias.[60]
Homeobox gene 1 (HESX1)
- The HESX1 gene, also called Rathke pouch homeobox (RPX), with OMIM number of 601802 is on chromosome 3p14.3, initially expressed during embryogenesis and help the formation of Rathke pouch and anterior pituitary.[61]
- HESX1 gene has an important role in pituitary development and midfacial differentiation. Mutation may lead to pituitary hypoplasia and decreased level of all anterior pituitary hormones.[62]
- Other disorders resulting from HESX1 mutation include septo optic dysplasia, reduced prosencephalon, anophthalmia, microphthalmia, defective olfactory development, Rathke pouch bifurcations, and abnormalities in the corpus callosum, hippocampus, and septum pellucidum.[61]
LIM homeobox gene 3 (LHX3)
- The LHX3 gene, also called LIM3, with OMIM number of 600577 is on chromosome 9q34.3, mainly expressed in developing anterior pituitary gland.[63]
- LHX3 gene function is important in development of pituitary gland and pituitary hormones secretion. Mutation in the LHX3 gene may result in combined pituitary hormone deficiency (CPHD).[64]
- LHX3 gene mutation may also result in neonatal hypoglycemia, short neck with limited rotation, mild sensorineural hearing loss, skin laxity, and skeletal abnormalities.[63]
PROP paired-like homeobox 1 (PROP1)
- The PROP1 gene with OMIM number of 601538 is on chromosome 5q35.3, with a role in developing anterior pituitary gland and associated cells such as gonadotrophs, thyrotrophs, somatotrophs, and lactotrophs.[65]
- Mutated PROP1 gene can lead to deficiency of LH, FSH, GH, TSH, and prolactin. Decreased level of LH and FSH may also delay or inhibit the onset of puberty.[66]
- Pituitary hormones have a vital role in regulating other endocrine organs via TRH, ACTH, FSH or LH and a mutation in PROP1 gene can lead to thyroid dysfunctions, growth retardation, and libido/lactation problems.
Leptin and leptin receptor (LEP and LEPR)
- The LEP and LEPR genes, also called OB and OBR, with OMIM numbers of 164160 and 601007 are on chromosomes 7q32.1 and 1p31.3, respectively; with a major role in modulation of body weight.
- These genes are believed to carry the message of onset of puberty. Recent studies have shown that recombinant leptin injection in female mice may result in puberty and cure their maturation (secondary sexual characteristics) problems.[67]
- It has been observed that leptin levels increase by 50% just before the onset of puberty and during puberty.[68]
- Mutation in LEP and LEPR genes may result in dysfunctional hematopoiesis, angiogenesis, wound healing, and the immune or inflammatory response.
Proprotein convertase 1 (PC1)
- The PC1 gene, also known as neuroendocrine convertase 1 (NEC1), with OMIM number of 162150 is on chromosome 5q15, and regulates neuroendocrine pathway.
- PC1 gene has a dominant role in proopiomelanocortin (POMC) cleavage. PC1 gene also has a role in processing proinsulin and proglucagon in pancreas.[69]
- Recent studies have shown that PC1 gene mutation and hypogonadotropic hypogonadism may result in extreme childhood obesity, abnormal glucose homeostasis, hypocortisolism, elevated plasma proinsulin, and POMC concentrations.[70]
Makorin RING-finger protein 3 (MKRN3)
- Newly discovered MKRN3 gene has a role in ubiquitination and cell signaling. The gene family proteins are majorly expressed in fetal brain during development, especially in arcuate nucleus.
- The process of gene amplification is on its peak after birth, which gradually declines with time, and finally rises again with onset of puberty. Thus MKRN3 gene is believed to be one of the factors in onset of puberty, along with kisspeptins and neurokinin B.[71]
Estrogen receptor α (ESR1)
- Estrogen receptor mutations are very rare, and were reported in a case report of delayed puberty.[72]
- Estradiol promotes breast maturation and provides negative feedback to hypothalamus and pituitary, by means of estrogen receptor α (encoded by ESR1 gene).[73]
- Female mice with mutated ESR1 gene have hypoplastic uterus with hemorrhage, multicystic ovary without corpus luteum; which is make them infertile.[74]
Associated Conditions
The associated conditions that are related to amenorrhea, are as following:[75]
Gross Pathology
- On gross pathology, normal endometrium in proliferative or luteal phases are characteristic findings of amenorrhea.
- In cases of amenorrhea which are secondary to other causes, the related gross pathology would be seen.
- Craniopharyngioma on gross pathology presents as cystic mass filled with motor oil-like fluid.[76]
Microscopic Pathology
- On microscopic histopathological analysis, craniopharyngioma as a cause of amenorrhea will have the following features:
- Trabecular squamous epithelium surrounded by palisaded columnar epithelium
- Small-to-medium sized cells with moderate amount of basophilic cytoplasm
- Bland nuclei
- Calcifications
- On microscopic histopathological analysis, pituitary adenoma as a cause of amenorrhea will have the following features:
- Loss of fibrous stroma
- Nested cells of normal anterior pituitary (based on the type of adenoma)
-
Craniopharyngioma; with psammoma bodies - by Jensflorian source: Librepathology
-
Craniopharyngioma; with calcification and two types of epithelium - by Sarahkayb source: Librepathology
-
Craniopharyngioma; multicystic texture - by Jensflorian source: Librepathology
-
Pituitary adenoma of lactotroph cells (prolactin producing) - by Jensflorian source: Librepathology
-
Pituitary adenoma of lactotroph cells (prolactin producing) regression after treatment - by Jensflorian source: Librepathology
-
Pituitary adenoma of thyrotroph cells (TSH producing) - by Jensflorian source: Librepathology
References
- ↑ Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, Sun SS (2003). "Age at menarche and racial comparisons in US girls". Pediatrics. 111 (1): 110–3. PMID 12509562.
- ↑ "Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign - ACOG".
- ↑ 3.0 3.1 Golden NH, Carlson JL (2008). "The pathophysiology of amenorrhea in the adolescent". Ann. N. Y. Acad. Sci. 1135: 163–78. doi:10.1196/annals.1429.014. PMID 18574222.
- ↑ Apter D (1997). "Development of the hypothalamic-pituitary-ovarian axis". Ann. N. Y. Acad. Sci. 816: 9–21. PMID 9238251.
- ↑ Boyar RM, Rosenfeld RS, Kapen S, Finkelstein JW, Roffwarg HP, Weitzman ED, Hellman L (1974). "Human puberty. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep". J. Clin. Invest. 54 (3): 609–18. doi:10.1172/JCI107798. PMC 301594. PMID 4852310.
- ↑ Wiksten-Almströmer M, Hirschberg AL, Hagenfeldt K (2007). "Menstrual disorders and associated factors among adolescent girls visiting a youth clinic". Acta Obstet Gynecol Scand. 86 (1): 65–72. doi:10.1080/00016340601034970. PMID 17230292.
- ↑ Perkins RB, Hall JE, Martin KA (2001). "Aetiology, previous menstrual function and patterns of neuro-endocrine disturbance as prognostic indicators in hypothalamic amenorrhoea". Hum. Reprod. 16 (10): 2198–205. PMID 11574516.
- ↑ Hebebrand J, Muller TD, Holtkamp K, Herpertz-Dahlmann B (2007). "The role of leptin in anorexia nervosa: clinical implications". Mol. Psychiatry. 12 (1): 23–35. doi:10.1038/sj.mp.4001909. PMID 17060920.
- ↑ Grinspoon S, Gulick T, Askari H, Landt M, Lee K, Anderson E, Ma Z, Vignati L, Bowsher R, Herzog D, Klibanski A (1996). "Serum leptin levels in women with anorexia nervosa". J. Clin. Endocrinol. Metab. 81 (11): 3861–3. doi:10.1210/jcem.81.11.8923829. PMID 8923829.
- ↑ Haas V, Onur S, Paul T, Nutzinger DO, Bosy-Westphal A, Hauer M, Brabant G, Klein H, Müller MJ (2005). "Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery". Am. J. Clin. Nutr. 81 (4): 889–96. PMID 15817868.
- ↑ Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J, Klibanski A (2004). "Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity". J. Clin. Endocrinol. Metab. 89 (7): 3486–95. doi:10.1210/jc.2003-032251. PMID 15240636.
- ↑ Katzman DK, Golden NH, Neumark-Sztainer D, Yager J, Strober M (2000). "From prevention to prognosis: clinical research update on adolescent eating disorders". Pediatr. Res. 47 (6): 709–12. PMID 10832726.
- ↑ Thong FS, McLean C, Graham TE (2000). "Plasma leptin in female athletes: relationship with body fat, reproductive, nutritional, and endocrine factors". J. Appl. Physiol. 88 (6): 2037–44. PMID 10846016.
- ↑ Weimann E, Blum WF, Witzel C, Schwidergall S, Böhles HJ (1999). "Hypoleptinemia in female and male elite gymnasts". Eur. J. Clin. Invest. 29 (10): 853–60. PMID 10583427.
- ↑ Welt, Corrine K.; Chan, Jean L.; Bullen, John; Murphy, Robyn; Smith, Patricia; DePaoli, Alex M.; Karalis, Aspasia; Mantzoros, Christos S. (2004). "Recombinant Human Leptin in Women with Hypothalamic Amenorrhea". New England Journal of Medicine. 351 (10): 987–997. doi:10.1056/NEJMoa040388. ISSN 0028-4793.
- ↑ Wieck A, Haddad PM (2003). "Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review". Br J Psychiatry. 182: 199–204. PMID 12611781.
- ↑ Magiakou MA, Mastorakos G, Webster E, Chrousos GP (1997). "The hypothalamic-pituitary-adrenal axis and the female reproductive system". Ann. N. Y. Acad. Sci. 816: 42–56. PMID 9238254.
- ↑ Seminara SB, Hayes FJ, Crowley WF (1998). "Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations". Endocr. Rev. 19 (5): 521–39. doi:10.1210/edrv.19.5.0344. PMID 9793755.
- ↑ Karavitaki N, Cudlip S, Adams CB, Wass JA (2006). "Craniopharyngiomas". Endocr. Rev. 27 (4): 371–97. doi:10.1210/er.2006-0002. PMID 16543382.
- ↑ Koutras DA (1997). "Disturbances of menstruation in thyroid disease". Ann. N. Y. Acad. Sci. 816: 280–4. PMID 9238278.
- ↑ Poppe K, Velkeniers B, Glinoer D (2007). "Thyroid disease and female reproduction". Clin. Endocrinol. (Oxf). 66 (3): 309–21. doi:10.1111/j.1365-2265.2007.02752.x. PMID 17302862.
- ↑ Speiser, Phyllis W.; White, Perrin C. (2003). "Congenital Adrenal Hyperplasia". New England Journal of Medicine. 349 (8): 776–788. doi:10.1056/NEJMra021561. ISSN 0028-4793.
- ↑ Gilling-Smith C, Story H, Rogers V, Franks S (1997). "Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome". Clin. Endocrinol. (Oxf). 47 (1): 93–9. PMID 9302378.
- ↑ Ehrmann DA, Barnes RB, Rosenfield RL (1995). "Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion". Endocr. Rev. 16 (3): 322–53. doi:10.1210/edrv-16-3-322. PMID 7671850.
- ↑ Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC (1998). "Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone". J. Clin. Endocrinol. Metab. 83 (2): 582–90. doi:10.1210/jcem.83.2.4604. PMID 9467578.
- ↑ Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R (1981). "Hypergonadotropic hypogonadism in female patients with galactosemia". N. Engl. J. Med. 304 (17): 994–8. doi:10.1056/NEJM198104233041702. PMID 6782485.
- ↑ Varner RE, Younger JB, Blackwell RE (1985). "Müllerian dysgenesis". J Reprod Med. 30 (6): 443–50. PMID 4020785.
- ↑ Edmonds DK (2003). "Congenital malformations of the genital tract and their management". Best Pract Res Clin Obstet Gynaecol. 17 (1): 19–40. PMID 12758224.
- ↑ Bonomi, Marco; Libri, Domenico Vladimiro; Guizzardi, Fabiana; Guarducci, Elena; Maiolo, Elisabetta; Pignatti, Elisa; Asci, Roberta; Persani, Luca (2011). "New understandings of the genetic basis of isolated idiopathic central hypogonadism". Asian Journal of Andrology. 14 (1): 49–56. doi:10.1038/aja.2011.68. ISSN 1008-682X.
- ↑ de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E (2003). "Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54". Proc. Natl. Acad. Sci. U.S.A. 100 (19): 10972–6. doi:10.1073/pnas.1834399100. PMC 196911. PMID 12944565.
- ↑ Seminara, Stephanie B.; Messager, Sophie; Chatzidaki, Emmanouella E.; Thresher, Rosemary R.; Acierno, James S.; Shagoury, Jenna K.; Bo-Abbas, Yousef; Kuohung, Wendy; Schwinof, Kristine M.; Hendrick, Alan G.; Zahn, Dirk; Dixon, John; Kaiser, Ursula B.; Slaugenhaupt, Susan A.; Gusella, James F.; O'Rahilly, Stephen; Carlton, Mark B.L.; Crowley, William F.; Aparicio, Samuel A.J.R.; Colledge, William H. (2003). "TheGPR54Gene as a Regulator of Puberty". New England Journal of Medicine. 349 (17): 1614–1627. doi:10.1056/NEJMoa035322. ISSN 0028-4793.
- ↑ Kaur KK, Allahbadia G, Singh M (2012). "Kisspeptins in human reproduction-future therapeutic potential". J Assist Reprod Genet. 29 (10): 999–1011. doi:10.1007/s10815-012-9856-1. PMC 3492584. PMID 23015158.
- ↑ Uenoyama, Yoshihisa; Tsukamura, Hiroko; Maeda, Kei-ichiro (2014). "KNDy neuron as a gatekeeper of puberty onset". Journal of Obstetrics and Gynaecology Research. 40 (6): 1518–1526. doi:10.1111/jog.12398. ISSN 1341-8076.
- ↑ Hardelin JP, Julliard AK, Moniot B, Soussi-Yanicostas N, Verney C, Schwanzel-Fukuda M, Ayer-Le Lievre C, Petit C (1999). "Anosmin-1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: implications for the developmental anomalies of X chromosome-linked Kallmann syndrome". Dev. Dyn. 215 (1): 26–44. doi:10.1002/(SICI)1097-0177(199905)215:1<26::AID-DVDY4>3.0.CO;2-D. PMID 10340754.
- ↑ Schwanzel-Fukuda M, Bick D, Pfaff DW (1989). "Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome". Brain Res. Mol. Brain Res. 6 (4): 311–26. PMID 2687610.
- ↑ 36.0 36.1 Trarbach EB, Silveira LG, Latronico AC (2007). "Genetic insights into human isolated gonadotropin deficiency". Pituitary. 10 (4): 381–91. doi:10.1007/s11102-007-0061-7. PMID 17624596.
- ↑ González-Martínez D, Kim SH, Hu Y, Guimond S, Schofield J, Winyard P, Vannelli GB, Turnbull J, Bouloux PM (2004). "Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism". J. Neurosci. 24 (46): 10384–92. doi:10.1523/JNEUROSCI.3400-04.2004. PMID 15548653.
- ↑ Hébert JM, Lin M, Partanen J, Rossant J, McConnell SK (2003). "FGF signaling through FGFR1 is required for olfactory bulb morphogenesis". Development. 130 (6): 1101–11. PMID 12571102.
- ↑ Tsai PS, Moenter SM, Postigo HR, El Majdoubi M, Pak TR, Gill JC, Paruthiyil S, Werner S, Weiner RI (2005). "Targeted expression of a dominant-negative fibroblast growth factor (FGF) receptor in gonadotropin-releasing hormone (GnRH) neurons reduces FGF responsiveness and the size of GnRH neuronal population". Mol. Endocrinol. 19 (1): 225–36. doi:10.1210/me.2004-0330. PMID 15459253.
- ↑ 40.0 40.1 Tornberg J, Sykiotis GP, Keefe K, Plummer L, Hoang X, Hall JE, Quinton R, Seminara SB, Hughes V, Van Vliet G, Van Uum S, Crowley WF, Habuchi H, Kimata K, Pitteloud N, Bülow HE (2011). "Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism". Proc. Natl. Acad. Sci. U.S.A. 108 (28): 11524–9. doi:10.1073/pnas.1102284108. PMC 3136273. PMID 21700882.
- ↑ Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M, Linhardt RJ (2004). "Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly". Biochemistry. 43 (16): 4724–30. doi:10.1021/bi0352320. PMID 15096041.
- ↑ Hudson ML, Kinnunen T, Cinar HN, Chisholm AD (2006). "C. elegans Kallmann syndrome protein KAL-1 interacts with syndecan and glypican to regulate neuronal cell migrations". Dev. Biol. 294 (2): 352–65. doi:10.1016/j.ydbio.2006.02.036. PMID 16677626.
- ↑ Matsumoto S, Yamazaki C, Masumoto KH, Nagano M, Naito M, Soga T, Hiyama H, Matsumoto M, Takasaki J, Kamohara M, Matsuo A, Ishii H, Kobori M, Katoh M, Matsushime H, Furuichi K, Shigeyoshi Y (2006). "Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2". Proc. Natl. Acad. Sci. U.S.A. 103 (11): 4140–5. doi:10.1073/pnas.0508881103. PMC 1449660. PMID 16537498.
- ↑ Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY (2001). "Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle". Mol. Pharmacol. 59 (4): 692–8. PMID 11259612.
- ↑ Cole LW, Sidis Y, Zhang C, Quinton R, Plummer L, Pignatelli D, Hughes VA, Dwyer AA, Raivio T, Hayes FJ, Seminara SB, Huot C, Alos N, Speiser P, Takeshita A, Van Vliet G, Pearce S, Crowley WF, Zhou QY, Pitteloud N (2008). "Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum". J. Clin. Endocrinol. Metab. 93 (9): 3551–9. doi:10.1210/jc.2007-2654. PMC 2567850. PMID 18559922.
- ↑ Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, Serin A, Mungan NO, Cook JR, Imamoglu S, Akalin NS, Yuksel B, O'Rahilly S, Semple RK (2009). "TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction". Nat. Genet. 41 (3): 354–358. doi:10.1038/ng.306. PMC 4312696. PMID 19079066.
- ↑ Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML (2004). "mRNA expression of tachykinins and tachykinin receptors in different human tissues". Eur. J. Pharmacol. 494 (2–3): 233–9. doi:10.1016/j.ejphar.2004.05.016. PMID 15212980.
- ↑ Semple RK, Topaloglu AK (2010). "The recent genetics of hypogonadotrophic hypogonadism - novel insights and new questions". Clin. Endocrinol. (Oxf). 72 (4): 427–35. doi:10.1111/j.1365-2265.2009.03687.x. PMID 19719764.
- ↑ Bouligand J, Ghervan C, Tello JA, Brailly-Tabard S, Salenave S, Chanson P, Lombès M, Millar RP, Guiochon-Mantel A, Young J (2009). "Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation". N. Engl. J. Med. 360 (26): 2742–8. doi:10.1056/NEJMoa0900136. PMID 19535795.
- ↑ Wu S, Wilson MD, Busby ER, Isaac ER, Sherwood NM (2010). "Disruption of the single copy gonadotropin-releasing hormone receptor in mice by gene trap: severe reduction of reproductive organs and functions in developing and adult mice". Endocrinology. 151 (3): 1142–52. doi:10.1210/en.2009-0598. PMID 20068010.
- ↑ Silveira LF, MacColl GS, Bouloux PM (2002). "Hypogonadotropic hypogonadism". Semin. Reprod. Med. 20 (4): 327–38. doi:10.1055/s-2002-36707. PMID 12536356.
- ↑ Tiong J, Locastro T, Wray S (2007). "Gonadotropin-releasing hormone-1 (GnRH-1) is involved in tooth maturation and biomineralization". Dev. Dyn. 236 (11): 2980–92. doi:10.1002/dvdy.21332. PMID 17948256.
- ↑ Kim HG, Kurth I, Lan F, Meliciani I, Wenzel W, Eom SH, Kang GB, Rosenberger G, Tekin M, Ozata M, Bick DP, Sherins RJ, Walker SL, Shi Y, Gusella JF, Layman LC (2008). "Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome". Am. J. Hum. Genet. 83 (4): 511–9. doi:10.1016/j.ajhg.2008.09.005. PMC 2561938. PMID 18834967.
- ↑ Kramer PR, Wray S (2000). "Novel gene expressed in nasal region influences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neurons". Genes Dev. 14 (14): 1824–34. PMC 316793. PMID 10898796.
- ↑ Corradi A, Croci L, Broccoli V, Zecchini S, Previtali S, Wurst W, Amadio S, Maggi R, Quattrini A, Consalez GG (2003). "Hypogonadotropic hypogonadism and peripheral neuropathy in Ebf2-null mice". Development. 130 (2): 401–10. PMID 12466206.
- ↑ Trarbach EB, Baptista MT, Garmes HM, Hackel C (2005). "Molecular analysis of KAL-1, GnRH-R, NELF and EBF2 genes in a series of Kallmann syndrome and normosmic hypogonadotropic hypogonadism patients". J. Endocrinol. 187 (3): 361–8. doi:10.1677/joe.1.06103. PMID 16423815.
- ↑ Guo W, Burris TP, McCabe ER (1995). "Expression of DAX-1, the gene responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis". Biochem. Mol. Med. 56 (1): 8–13. PMID 8593542.
- ↑ 58.0 58.1 Kojima Y, Sasaki S, Hayashi Y, Umemoto Y, Morohashi K, Kohri K (2006). "Role of transcription factors Ad4bp/SF-1 and DAX-1 in steroidogenesis and spermatogenesis in human testicular development and idiopathic azoospermia". Int. J. Urol. 13 (6): 785–93. doi:10.1111/j.1442-2042.2006.01403.x. PMID 16834661.
- ↑ Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP, McCabe ER (1994). "An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita". Nature. 372 (6507): 635–41. doi:10.1038/372635a0. PMID 7990953.
- ↑ Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA (1998). "Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression". Cell. 93 (3): 445–54. PMID 9590178.
- ↑ 61.0 61.1 Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Mårtensson IL, Toresson H, Fox M, Wales JK, Hindmarsh PC, Krauss S, Beddington RS, Robinson IC (1998). "Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse". Nat. Genet. 19 (2): 125–33. doi:10.1038/477. PMID 9620767.
- ↑ Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, Cameron F, Hurst J, Woods K, Dunger D, Stanhope R, Forrest S, Robinson IC, Beddington RS (2001). "Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia". Hum. Mol. Genet. 10 (1): 39–45. PMID 11136712.
- ↑ 63.0 63.1 Rajab A, Kelberman D, de Castro SC, Biebermann H, Shaikh H, Pearce K, Hall CM, Shaikh G, Gerrelli D, Grueters A, Krude H, Dattani MT (2008). "Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss". Hum. Mol. Genet. 17 (14): 2150–9. doi:10.1093/hmg/ddn114. PMID 18407919.
- ↑ Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, Moers A, Goossens M, Grüters A, Amselem S (2000). "Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency". Nat. Genet. 25 (2): 182–6. doi:10.1038/76041. PMID 10835633. Vancouver style error: initials (help)
- ↑ Duquesnoy P, Roy A, Dastot F, Ghali I, Teinturier C, Netchine I, Cacheux V, Hafez M, Salah N, Chaussain JL, Goossens M, Bougnères P, Amselem S (1998). "Human Prop-1: cloning, mapping, genomic structure. Mutations in familial combined pituitary hormone deficiency". FEBS Lett. 437 (3): 216–20. PMID 9824293.
- ↑ Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O'Connell SM, Flynn SE, Brown MR, Mullis PE, Parks JS, Phillips JA, Rosenfeld MG (1998). "Mutations in PROP1 cause familial combined pituitary hormone deficiency". Nat. Genet. 18 (2): 147–9. doi:10.1038/ng0298-147. PMID 9462743.
- ↑ Chehab FF, Lim ME, Lu R (1996). "Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin". Nat. Genet. 12 (3): 318–20. doi:10.1038/ng0396-318. PMID 8589726.
- ↑ Mantzoros CS, Flier JS, Rogol AD (1997). "A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty". J. Clin. Endocrinol. Metab. 82 (4): 1066–70. doi:10.1210/jcem.82.4.3878. PMID 9100574.
- ↑ Jansen E, Ayoubi TA, Meulemans SM, Van de Ven WJ (1995). "Neuroendocrine-specific expression of the human prohormone convertase 1 gene. Hormonal regulation of transcription through distinct cAMP response elements". J. Biol. Chem. 270 (25): 15391–7. PMID 7797529.
- ↑ Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S (1997). "Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene". Nat. Genet. 16 (3): 303–6. doi:10.1038/ng0797-303. PMID 9207799.
- ↑ Hughes, Ieuan A. (2013). "Releasing the Brake on Puberty". New England Journal of Medicine. 368 (26): 2513–2515. doi:10.1056/NEJMe1306743. ISSN 0028-4793.
- ↑ Quaynor, Samuel D.; Stradtman, Earl W.; Kim, Hyung-Goo; Shen, Yiping; Chorich, Lynn P.; Schreihofer, Derek A.; Layman, Lawrence C. (2013). "Delayed Puberty and Estrogen Resistance in a Woman with Estrogen Receptor α Variant". New England Journal of Medicine. 369 (2): 164–171. doi:10.1056/NEJMoa1303611. ISSN 0028-4793.
- ↑ Christian CA, Glidewell-Kenney C, Jameson JL, Moenter SM (2008). "Classical estrogen receptor alpha signaling mediates negative and positive feedback on gonadotropin-releasing hormone neuron firing". Endocrinology. 149 (11): 5328–34. doi:10.1210/en.2008-0520. PMC 2584581. PMID 18635656.
- ↑ Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O (1993). "Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene". Proc. Natl. Acad. Sci. U.S.A. 90 (23): 11162–6. PMC 47942. PMID 8248223.
- ↑
- ↑ Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Strojan P, Suárez C, Genden EM, Rinaldo A, Ferlito A (2012). "Craniopharyngioma: a pathologic, clinical, and surgical review". Head Neck. 34 (7): 1036–44. doi:10.1002/hed.21771. PMID 21584897.